USPTO Examiner MCDOWELL BRIAN E - Art Unit 1624

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19240239HETEROARYL COMPOUNDS, SOLID FORMS, PREPARATION METHODS AND USES THEREOFJune 2025February 2026Allow811YesNo
19223498SUBSTITUTED INDOLE COMPOUNDS AND METHODS OF USE THEREOFMay 2025January 2026Allow821YesNo
19183531TARGETED PROTEIN DEGRADATIONApril 2025July 2025Allow201NoNo
19058521PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORSFebruary 2025September 2025Allow711YesNo
18975881SELECTIVE ANGIOTENSIN II COMPOUNDSDecember 2024July 2025Allow711YesNo
18917653NLRP3 INFLAMMASOME INHIBITORSOctober 2024March 2025Allow511YesNo
18804311NOVEL SUBSTITUTED PYRAZINE-CARBOXAMIDE DERIVATIVESAugust 2024January 2025Allow511YesNo
18777202PARP1 INHIBITORS AND USES THEREOFJuly 2024December 2024Allow510NoNo
18770015PHTHALAZINONE BASED MODULATORS FOR THE TREATMENT OF DISEASEJuly 2024July 2025Allow1222YesNo
18754527OXOINDOLINYL AMIDE DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOFJune 2024September 2025Allow1521YesNo
187367105-(SUBSTITUTEDPHENYL)-7-THIOXO-7,8-DIHYDROPYRIMIDO[4,5-d]PYRIMIDINE-2,4(1H,3H)-DIONE ANALOGUES AS ANTIBACTERIAL AGENTSJune 2024October 2024Allow510NoNo
18661628POLYDENTATE ORGANIC LIGAND, METALLO-SUPRAMOLECULAR POLYMER, POLYMER FILM AND PREPARATION METHOD THEREOFMay 2024September 2025Allow1711NoNo
186238085-((2-ISOPROPYL-5-METHYLPHENOXY)METHYL)-3-(NAPHTHALEN-1-YL)-1,2,4-OXADIAZOLE AS AN ANTI-CANCER AND ANTIMICROBIAL COMPOUNDApril 2024June 2024Allow300YesNo
186235445-((2-ISOPROPYL-5-METHYLPHENOXY)METHYL)-3-(NAPHTHALEN-1-YL)-1,2,4-OXADIAZOLE AS AN ANTI-CANCER AND ANTIMICROBIAL COMPOUNDApril 2024September 2024Allow510NoNo
186188245-(SUBSTITUTEDPHENYL)-7-THIOXO-7,8-DIHYDROPYRIMIDO[4,5-d]PYRIMIDINE-2,4(1H,3H)-DIONE ANALOGUES AS ANTIBACTERIAL AGENTSMarch 2024November 2024Allow711YesNo
18692791AHR INHIBITOR, USE THEREOF, AND PREPARATION METHOD THEREFORMarch 2024March 2025Abandon1321YesNo
18595801Belumosudil Metabolites and Uses Thereof In The Treatment of Chronic Graft-Versus-Host DiseaseMarch 2024January 2026Allow2311NoNo
18688683THERAPEUTIC COCRYSTALS OF 3-{[5-(AZETIDINE-1-YLCARBONYL)PYRAZIN-2-YL]OXY}-5-{[(1S)-1-METHYL-2-(METHYLOXY)ETHYL]OXY)-N-(5-METHYLPYRAZIN-2-YL)BENZAMIDEMarch 2024March 2025Allow1311YesNo
18590749Chemically Coupled Transporter for Low-Hydrophobicity Bioactive Drugs into the Central Nervous SystemFebruary 2024January 2026Allow2311NoNo
18586620TRIAZOLE-SUBSTITUTED IMIDAZO[1,2-A]PYRIMIDINES AS CGAS INHIBITORSFebruary 2024August 2024Allow611YesNo
18443925KRAS G12C INHIBITORS AND METHODS OF USING THE SAMEFebruary 2024August 2025Abandon1801NoNo
184346017-(4-((5-(2-CHLOROBENZYLIDENEAMINO)-2-THIOXO-1,3,4-THIADIAZOL-3(2H)-YL)METHYL)PIPERAZIN-1-YL)-1-CYCLOPROPYL-6-FLUORO-4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID AS AN ANTI-INFLAMMATORY COMPOUNDFebruary 2024April 2024Allow200YesNo
184304002-[(1H-BENZIMIDAZOL-2-YL)IMINO]-5,5-DIPHENYLIMIDAZOLIDIN-4-ONE AS AN ANTIMICROBIAL COMPOUNDFebruary 2024August 2024Allow610NoNo
18428046SUBSTITUTED PYRIDINE N-OXIDE DERIVATIVES USEFUL AS A FACTOR XIA INHIBITORSJanuary 2024October 2025Abandon2011NoNo
18422258INHIBITORS OF RETJanuary 2024February 2026Allow2411NoNo
18393915SOLID STATE FORMS OF BELUMOSUDIL AND BELUMOSUDIL SALTSDecember 2023August 2024Allow711NoNo
18391047PYRAZOLOPYRIMIDINE COMPOUNDSDecember 2023June 2025Abandon1801NoNo
18536912PYRROLO[3,2-C]QUINOLINE-2,3-DIONE COMPOUNDS AS CK2 INHIBITORSDecember 2023April 2024Allow411YesNo
18533073PYRROLO[3,2-C]QUINOLINE COMPOUNDS AS CK2 INHIBITORSDecember 2023March 2024Allow311NoNo
18532293PYRAZINE COMPOUNDDecember 2023May 2025Abandon1701NoNo
18533067PYRROLO[3,2-C]QUINOLINE COMPOUNDS AS CK2 INHIBITORSDecember 2023March 2024Allow301YesNo
183887345-(SUBSTITUTEDPHENYL)-7-THIOXO-7,8-DIHYDROPYRIMIDO[4,5- d]PYRIMIDINE-2,4(1H,3H)-DIONE ANALOGUES AS ANTIBACTERIAL AGENTSNovember 2023September 2024Abandon1111NoNo
183865455-((2-ISOPROPYL-5-METHYLPHENOXY)METHYL)-3-(NAPHTHALEN-1-YL)-1,2,4-OXADIAZOLE AS AN ANTI-CANCER AND ANTIMICROBIAL COMPOUNDNovember 2023March 2024Allow411NoNo
18384080PROCESS FOR THE PREPARATION OF PYRIMIDINYL-4-AMINOPYRAZOLE COMPOUNDSOctober 2023August 2025Allow2201YesNo
183828052-[(1H-BENZIMIDAZOL-2-YL)IMINO]-5,5-DIPHENYLIMIDAZOLIDIN-4-ONE AS AN ANTIMICROBIAL COMPOUNDOctober 2023August 2024Abandon911NoNo
18491686DERIVATIVES OF ARYL HYDROCARBON RECEPTOR AGONISTSOctober 2023September 2025Allow2311YesNo
18377125ASK1 INHIBITING AGENTSOctober 2023May 2025Allow1911NoNo
18372115BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOFSeptember 2023April 2024Allow711YesNo
18368362Pyrimidine Derivative, Method For Preparing Same And Use Thereof In MedicineSeptember 2023April 2025Allow1911NoNo
18244644PYRROLO[3,4-B]QUINOLINE COMPOUNDS AS ANTIBACTERIAL AGENTSSeptember 2023January 2024Allow411YesNo
18244281BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOFSeptember 2023November 2023Allow310NoNo
18242753PYRROLO[3,2-C]QUINOLINE COMPOUNDS AS CK2 INHIBITORSSeptember 2023February 2024Allow511NoNo
182413837-(4-((5-(BENZYLIDENEAMINO)-2-THIOXO-1,3,4-THIADIAZOL-3(2H)-YL)METHYL)PIPERAZIN-1-YL)-1-CYCLOPROPYL-6-FLUORO-4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID AS AN ANTI-INFLAMMATORY AND ANTICANCER COMPOUNDSeptember 2023February 2024Allow521YesNo
18240853HDAC INHIBITOR SOLID STATE FORMSAugust 2023August 2024Allow1100NoNo
18455865HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORSAugust 2023June 2025Allow2211YesNo
18236458SOLID STATE FORMS OF BELUMOSUDIL AND BELUMOSUDIL SALTSAugust 2023November 2023Allow301YesNo
182349735-(3-SUBSTITUTED PHENYL)-PYRIMIDO[4,5-d]PYRIMIDINE-2,4,7(1H,3H,8H)-TRIONE DERIVATIVES AS ANTICANCER AGENTSAugust 2023January 2024Allow511YesNo
182320125-(SUBSTITUTEDPHENYL)-7-THIOXO-7,8-DIHYDROPYRIMIDO[4,5-d]PYRIMIDINE-2,4(1H,3H)-DIONE ANALOGUES AS ANTIBACTERIAL AGENTSAugust 2023September 2024Abandon1321NoNo
18353410INHIBITORS OF NLRP3 INFLAMMASOMEJuly 2023August 2025Allow2521NoNo
18353370INHIBITORS OF NLRP3 INFLAMMASOMEJuly 2023May 2025Allow2211YesNo
18352078MK2 INHIBITORS AND USES THEREOFJuly 2023November 2023Allow410NoNo
18333262HETEROARYL-BIPHENYL AMIDES FOR THE TREATMENT OF PD-L1 DISEASESJune 2023June 2025Allow2411NoNo
18333459PRODRUG OF PYRROLIDONE DERIVATIVES AS GLUCOKINASE ACTIVATORJune 2023March 2024Allow911YesNo
18331758PYRIMIDINE SMALL-MOLECULE COMPOUND AND APPLICATION THEREOFJune 2023November 2023Allow501YesNo
18266156COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITYJune 2023March 2026Abandon3301NoNo
18327775CHECKPOINT KINASE 1 (CHK1) INHIBITORS AND USES THEREOFJune 2023September 2025Allow2721YesNo
18323939INHIBITORS OF NLRP3 INFLAMMASOMEMay 2023January 2026Allow3231NoNo
18196601PYRIDAZINONES AS PARP7 INHIBITORSMay 2023August 2025Allow2711NoNo
18143975COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORSMay 2023July 2025Allow2621NoNo
18310943MK2 INHIBITORS AND USES THEREOFMay 2023September 2025Allow2921YesNo
18310463CRYSTALLINE COMPOSITION OF TILDACERFONT AND METHODS OF USE AND PREPARATION THEREOFMay 2023May 2025Abandon2411NoNo
18309164NOVEL PYRIMIDINES AS EGFR-INHIBITORS AND METHODS OF TREATING DISORDERSApril 2023February 2025Allow2211YesNo
18309031MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOFApril 2023August 2025Allow2821YesNo
18306236RING-MODIFIED PROLINE SHORT PEPTIDE COMPOUND AND USE THEREOFApril 2023May 2024Allow1321YesNo
18133666CRYSTALLINE SUBSTITUTED PYRAZINES AS PGI2 RECEPTOR AGONISTSApril 2023July 2024Allow1501NoNo
18126646ENZYME INHIBITORSMarch 2023October 2024Abandon1901NoNo
18125449PYRROLO[3,4-B]QUINOLINE COMPOUNDS AS ANTIBACTERIAL AGENTSMarch 2023August 2023Allow511YesNo
18027870ALBICIDIN DERIVATIVES, THEIR USE AND SYNTHESISMarch 2023February 2026Abandon3501NoNo
18184766COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOFMarch 2023May 2025Allow2611YesNo
18121318Chemically Coupled Transporter for Low-Hydrophobicity Bioactive Drugs into the Central Nervous SystemMarch 2023December 2023Allow911YesNo
18183039METHOD FOR PRODUCING 3,6-DISUBSTITUTED-IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVEMarch 2023January 2026Abandon3430NoNo
18120806CDK INHIBITORSMarch 2023October 2025Allow3220NoNo
18179841DERIVATIVES OF ARYL HYDROCARBON RECEPTOR AGONISTSMarch 2023October 2023Allow721YesNo
18117847COMPOUNDS WITH TUBULIN POLYMERISATION INHIBITORY ACTIVITY AND IMMUNOMODULATORY PROPERTIESMarch 2023March 2025Allow2521NoNo
18176107Porphyrin Compounds and Compositions Useful for Treating CancerFebruary 2023June 2025Abandon2711NoNo
18115314AZETIDINE AND PYRROLIDINE PARP1 INHIBITORS AND USES THEREOFFebruary 2023September 2023Allow611NoNo
18174983Organic Electroluminescent Element And Novel Iridium ComplexFebruary 2023February 2026Allow3521YesNo
18110626HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORSFebruary 2023September 2024Abandon1901NoNo
18105427Belumosudil Metabolites and Uses Thereof In The Treatment of Chronic Graft-Versus-Host DiseaseFebruary 2023December 2023Allow1011YesNo
18104655PYRAZOLE DERIVATIVES FOR THE TREATMENT OF CYSTIC FIBROSISFebruary 2023April 2025Allow2711NoNo
18162127FGFR INHIBITORS AND METHODS OF USE THEREOFJanuary 2023May 2023Allow300NoNo
18102359PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERSJanuary 2023October 2024Abandon2101NoNo
18160240ORGANIC MOLECULES FOR USE IN OPTOELECTRONIC DEVICESJanuary 2023May 2025Allow2721YesNo
18099770PARP1 INHIBITORS AND USES THEREOFJanuary 2023November 2023Allow921YesNo
18096397INHIBITOR OF INDOLEAMINE 2,3-DIOXYGENASE-1 AND METHODS OF MANUFACTURE AND USE THEREOFJanuary 2023August 2025Abandon3121NoNo
18151688PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORSJanuary 2023April 2025Allow2711NoNo
18149740CLEAVABLE AGENTSJanuary 2023September 2025Abandon3211NoNo
18003849ORGANIC COMPOUND AND ELECTRONIC DEVICE AND ELECTRONIC APPARATUS THEREOFDecember 2022June 2024Allow1721YesNo
18081951Methods for the Prevention and Treatment of Hearing LossDecember 2022February 2026Allow3841YesNo
18066507METHODS AND COMPOSITIONS FOR TARGETING PD-L1December 2022April 2025Allow2811YesNo
18080566HDAC INHIBITOR SOLID STATE FORMSDecember 2022August 2023Allow811YesNo
18079617PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERSDecember 2022January 2024Allow1321NoNo
18075513SOLID STATE FORMS OF BELUMOSUDIL AND BELUMOSUDIL SALTSDecember 2022July 2023Allow811YesNo
18075853NITROGEN CONTAINING HETEROCYCLES AS CDK12 INHIBITORSDecember 2022March 2025Allow2821YesNo
18075270PTERIDINONE COMPOUNDS AND USES THEREOFDecember 2022January 2025Allow2610NoNo
17980186COMPOSITIONS RELATED TO SUBSTITUTED PYRAZINES AS CTPS INHIBITORSNovember 2022May 2025Allow3011YesNo
17968408Methods and Compositions of 4-Substituted Benzoylpiperazine-1-Substituted Carbonyls as Beta-Catenin/B-Cell Lymphoma 9 ImhibitorsOctober 2022January 2025Allow2711NoNo
179658432,6-DIAMINO-3,4-DIHYDROPYRIMIDIN-4-ONE DERIVATIVES AND USE THEREOF IN THERAPYOctober 2022March 2025Allow2911YesNo
17957584AZETIDINE AND PYRROLIDINE PARP1 INHIBITORS AND USES THEREOFSeptember 2022August 2023Abandon1111NoNo
17946236CRYSTALLINE FORMS OF PIPERAZINE-1,4-DIYLBIS((6-(1H-BENZO[D]IMIDAZO-2-YL)PYRIDIN-2YL)METHANONE)September 2022February 2025Allow2911YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MCDOWELL, BRIAN E.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
5
Examiner Affirmed
4
(80.0%)
Examiner Reversed
1
(20.0%)
Reversal Percentile
31.0%
Lower than average

What This Means

With a 20.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
69
Allowed After Appeal Filing
15
(21.7%)
Not Allowed After Appeal Filing
54
(78.3%)
Filing Benefit Percentile
28.6%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 21.7% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner MCDOWELL, BRIAN E - Prosecution Strategy Guide

Executive Summary

Examiner MCDOWELL, BRIAN E works in Art Unit 1624 and has examined 1,393 patent applications in our dataset. With an allowance rate of 66.1%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 24 months.

Allowance Patterns

Examiner MCDOWELL, BRIAN E's allowance rate of 66.1% places them in the 27% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.

Office Action Patterns

On average, applications examined by MCDOWELL, BRIAN E receive 1.55 office actions before reaching final disposition. This places the examiner in the 28% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by MCDOWELL, BRIAN E is 24 months. This places the examiner in the 81% percentile for prosecution speed. Applications move through prosecution relatively quickly with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +36.0% benefit to allowance rate for applications examined by MCDOWELL, BRIAN E. This interview benefit is in the 84% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 27.9% of applications are subsequently allowed. This success rate is in the 50% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 35.6% of cases where such amendments are filed. This entry rate is in the 53% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 14.3% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 25% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 86.8% of appeals filed. This is in the 80% percentile among all examiners. Of these withdrawals, 78.8% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 66.7% are granted (fully or in part). This grant rate is in the 71% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 5.6% of allowed cases (in the 87% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 10.2% of allowed cases (in the 89% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.